Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A08105 | Pages: 200 | Charts: 67 | Tables: 128 |
The global cancer stem cells market size was $1.1 billion in 2021 and is projected to reach $2.7 billion by 2031, growing at a CAGR of 10% from 2022 to 2031. Cancer stem cells (CSCs) are small subpopulations of cells that are capable of self-renewal, differentiation, and tumorigenicity, as well as they, give rise to every type of cell seen in a specific cancer sample.
Get more information on this report : Request Sample Pages
Cancer stem cells are unique in that they can differentiate into several lineages and have the potential to multiply greatly, among other things. The majority of tissues, including the brain, prostate, lungs, and other tissues, include these cells. Cancer therapy benefits greatly from the use of cancer stem cells. It's critical to comprehend the numerous relationships between stem cells and cancer. For instance, stem cell technology focuses on fighting cancer-causing disorders while also providing vital information regarding the cause of the disease.
Major factors driving cancer stem cells market include an increase in R&D activities that facilitates the development of medications to treat cancer, which is the leading cause of death globally. Additionally, the need for a safe and efficient treatment that will completely destroy cancer cells in the body while reducing the patient's risk of relapse or metastasis has increased due to the rising incidence of cancer worldwide. As a result, funding for new treatment technology and cancer-related research studies is increasing rapidly. These factors are anticipated to fuel the cancer stem cell market growth in the forecasted time period.
The clinical procedures involved in stem cell transplantation are critical and involve high risk, such as the radiation therapy that is used to diagnose different types of cancer. For instance, when aggressive tumors are treated with very high doses of radiation therapy, the blood-forming and leukocyte cells are either completely or partially destroyed. In such cases, the patients require an infusion of hematopoietic stem cell transplant, either allogeneic or autologous. Such medical procedures are very costly due to which the middle-class and lower-class sectors have less awareness and access to such therapies. These factors are anticipated to hamper the growth of the cancer stem cell market in forecast time period.
According to the estimates provided by the World Health Organization (WHO), cancer accounted for about 10 million deaths in 2020, making it one of the top causes of mortality. The demand for efficient medicines and transplantation caused by the rise in cancer types like lymphoma, leukemia, osteopetrosis, and other diseases is leading to extensive research in the cancer stem cells. The market for cancer stem cells is expanding as a result of growing investment possibilities provided by the government, top biomedical businesses, and clinical R&D activities conducted globally. Leading pharmaceutical and biomedical businesses are working on innovating new cancer therapy for the treatment of cancer using cancer stem cell. Stem cell-based technology can provide several opportunities in field of cancer therapy. Stem cells can reach solid tumors and micro metastatic lesions to administer anti-tumor agents. In order to avoid the short half-lives of standard antitumor medicines, stem cells can be engineered to express a variety of antitumor agents. The mechanism of stem cells may enhance stem cell-based regeneration medicine as well as anticancer methods that will ultimately play important role in the widespread clinical use of stem cells therapy.
The industry players are investing a lot of efforts in the research and development of smart and unique strategies to sustain their growth in the market. These strategies include product launches, mergers & acquisitions, collaborations, partnerships, and refurbishing of existing technology. On June 8, 2022, BlueRock Therapeutics LP, a biopharmaceutical firm and wholly-owned subsidiary of Bayer AG, announced the establishment of a new cell treatment innovation site on Bayer's campus in Berlin, Germany. While working independently, the BlueRock team will take advantage of the knowledge held by multiple Bayer departments in order to expand and expedite the company's clinical studies to Europe.
The key players profiled in this report include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.
The global cancer stem cells market is segmented on the basis of cancer forms, application, and region. By cancer forms, the market is sub-segmented into breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and others. By application, the market is classified into targeted cancerous stem cells, stem cell-based cancer therapy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The cancer stem cells market is segmented into Cancer Forms and Application.
[CANCERFORMSGRAPH]
By cancer forms, the breast cancer sub-segment dominated the cancer stem cells market in 2021. Breast cancer is one of the most common diseases affecting women globally. The established risk factors for breast cancer include advancing age, reproductive variables, mammographic density, and genetic factors and family history. Numerous other elements, including dietary fat intake, alcohol consumption, exposure to solvents, and pesticides, have also been suggested as potential risk elements for breast cancer among females. The incidence of breast cancer is steadily rising in most industrialized nations and in communities that have recently undergone or are undergoing westernization such as change in lifestyles, pollution, change in diet and physical activity patterns. These are predicted to be the major factors affecting the cancer stem cells market size during the forecast period.
By cancer forms, the bladder cancer sub-segment shows the fastest growth in the cancer stem cells market in 2021. The ninth most common disease in the world is the bladder cancer. The bladder cancer is a malignant development of aberrant cells. Inhaling carcinogens from the environment, including cigarette smoke, volatile coal tar compounds, cooking hood smoke, and diesel exhaust can lead to bladder cancer. The main known cause of bladder cancer in the majority of population is smoking. About half of bladder cancer cases are caused by smoking. Smoking cessation was linked to a lower risk of bladder cancer, just like it was for many other malignancies caused by smoking. These factors are anticipated to fuel the growth of cancer cell stems market for bladder cancer during the forecast period time.
[APPLICATIONGRAPH]
By application, the stem cell-based cancer therapy sub-segment dominated the global cancer stem cells market share in 2021. Traditional surgical or chemo radiotherapeutic methods typically cannot eradicate metastatic cancer cells, and disease recurrence is very common in such cases, after the treatment. On the other hand, stem cell-based therapies are becoming more and more promising for the treatment of cancer. By focusing on both metastatic tumor foci and primary stem cells, novel delivery strategies can be developed. In preclinical animal models, stem cells modified to persistently express different cytotoxic drugs reduce tumor sizes and lengthen longevity have shown positive results. Additionally, they have been used as viral and nanoparticle carriers to improve primary therapeutic efficacies and lessen side effects of treatment. Additionally, stem cells can be used in cancer stem cell-targeted therapy, immunotherapy, and applications for anticancer drug screening.
[REGIONGRAPH]
By region, North America dominated the global cancer market size in 2021 and is projected to remain the fastest-growing sub-segment during the forecast period. North America has well-established healthcare and medical research facilities. The United States is one of the top locations for cutting-edge research and development in cancer stem cells and has a sizably large budget. The existence of numerous renowned biomedical research institutions and their active involvement in the development of novel therapies and transplants are projected to support the market's expected revenue growth in this area. The availability of cutting-edge research infrastructure, the involvement of numerous important medical institutes, the rise in research and development initiatives to create therapeutic options for chronic diseases, and the ease with which clinical trial approval can be granted are all expected to contribute to market growth.
Key Market Segments
Key Market Players